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Hypertension complicates ≤10% of pregnancies world-wide, and it is a leading cause of maternal and perinatal 
mortality and morbidity, in well and less-resourced settings. 
Hypertension may be because of chronic hypertension (≈1% 
of pregnancies), gestational hypertension (≈6%), or pre-
eclampsia (≈3%) that appears de novo or evolves from chronic 
or gestational hypertension.1 Although preeclampsia is associ-
ated with the greatest maternal and perinatal risks, those risks 
are also elevated in women with chronic or gestational hyper-
tension who are twice as prevalent.
Management of pregnancy hypertension is multifaceted. 
Although some decisions are dependent on the hypertensive 
disorder (such as prevention of progression to preeclampsia 
among women with chronic hypertension or administration 
of magnesium sulfate to women with eclampsia), decisions 
about antihypertensive therapy are common to all hyperten-
sive pregnant women. It has been recognized that antihyper-
tensive for nonsevere hypertension decreases the incidence of 
severe hypertension and additional antihypertensive therapy,2 
but the concern has been that this may be achieved at the 
expense of fetal growth and well-being3,4; the latter meta-anal-
ysis of von Dadelszen et al3 showed that a greater antihyper-
tensive-induced fall in mean arterial pressure was associated 
with a higher proportion of small-for-gestational-age infants, 
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Abstract—For hypertensive women in CHIPS (Control of Hypertension in Pregnancy Study), we assessed whether the maternal 
benefits of tight control could be achieved, while minimizing any potentially negative effect on fetal growth, by delaying 
initiation of antihypertensive therapy until later in pregnancy. For the 981 women with nonsevere, chronic or gestational 
hypertension randomized to less-tight (target diastolic blood pressure, 100 mm Hg), or tight (target, 85 mm Hg) control, we 
used mixed-effects logistic regression to examine whether the effect of less-tight (versus tight) control on major outcomes 
was dependent on gestational age at randomization, adjusting for baseline factors as in the primary analysis and including 
an interaction term between gestational age at randomization and treatment allocation. Gestational age was considered 
categorically (quartiles) and continuously (linear or quadratic form), and the optimal functional form selected to provide 
the best fit to the data based on the Akaike information criterion. Randomization before (but not after) 24 weeks to less-tight 
(versus tight) control was associated with fewer babies with birth weight <10th centile (Pinteraction=0.005), but more preterm 
birth (Pinteraction=0.043), and no effect on perinatal death or high-level neonatal care >48 hours (Pinteraction=0.354). For the mother, 
less-tight (versus tight) control was associated with more severe hypertension at all gestational ages but particularly so before 
28 weeks (Pinteraction=0.076). In women with nonsevere, chronic, or gestational hypertension, there seems to be no gestational 
age at which less-tight (versus tight) control is the preferred management strategy to optimize maternal or perinatal outcomes.
Clinical Trial Registration—URL: https://www.isrctn.com. Unique identifier: ISRCTN71416914.
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based on 14 trials (slope, 0.09; SD, 0.03; r2, 0.48; P=0.006). 
However, the absolute decrease in birth weight was 145 g for 
each 10-mm Hg fall in mean arterial pressure.
The CHIPS (Control of Hypertension in Pregnancy Study; 
ISRCTN 71416914, http://pre-empt.cfri.ca/CHIPS) compared 
the effectiveness of less-tight versus tight blood pressure (BP) 
control in improving pregnancy outcomes among women 
with nonsevere, nonproteinuric chronic or gestational hyper-
tension at 14 to 33 weeks of pregnancy.5 In the CHIPS trial, 
987 women were randomized to less-tight control (n=497; 
target diastolic BP [dBP] of 100 mm Hg) versus tight con-
trol (n=490; target dBP of 85 mm Hg); a planned 15 mm Hg 
difference in dBP goals aimed to achieve a 5-mm Hg actual 
difference in dBP, which was the case; mean systolic BP in 
less-tight control was 138.8±0.5 mm Hg (versus 133.1±0.3 
mm Hg in tight), and mean dBP in less-tight control was 
89.9±0.3 mm Hg (versus 85.3±0.3 mm Hg in tight). No sta-
tistically significant differences were seen in the primary peri-
natal outcome of perinatal death or high-level neonatal care 
for >48 hours (155, 31.4% versus 150, 30.7%; adjusted odds 
ratio [OR], 1.02 [0.77–1.35]; P=0.89) or secondary maternal 
outcome of serious maternal complications, including death 
(18, 3.7% versus 10, 2.0%; adjusted OR, 1.74 [0.79–3.84]; 
P=0.17). However, women in less-tight (versus tight) control 
more often developed severe maternal hypertension (200, 
40.6% versus 134, 27.5%; adjusted OR, 1.80 [1.34–2.38]; 
P<0.001), platelet count <100×109 per liter (21, 4.3% versus 
8, 1.6%; adjusted OR, 2.63 [1.15–6.05]; P=0.02), and elevated 
liver enzymes with maternal symptoms (21, 4.3% versus 9, 
1.8%; adjusted odds ratio, 2.33 [1.05–5.16]; P=0.03). In 
exploratory analyses, severe hypertension was associated with 
an excess of adverse perinatal and maternal outcomes, espe-
cially in less-tight control and even after adjustment for the 
co-occurrence of preeclampsia.6
Taken together, the CHIPS results suggest that tight control 
might be the best clinical option because it minimizes mater-
nal risk without increasing perinatal risk. However, some cli-
nicians are concerned that in tight (versus less tight) control, 
there may have been an increase in birth weight <10th centile 
of potential clinical importance (96, 19.7% versus 79, 16.1%, 
respectively; adjusted OR, 1.28 [0.93–1.79]; P=0.14); the lack 
of statistical significance may have reflected a lack of statisti-
cal power, particularly for women with chronic hypertension.7 
However, what has not been highlighted is that in tight (ver-
sus less-tight) control, there was also a nonsignificant trend 
of similar magnitude toward a decrease in preterm birth (153, 
31.5% versus 175, 35.6%, respectively; adjusted OR, 0.85 
[0.64–1.11]; P=0.18). These surrogate outcomes for adverse 
perinatal outcome may have balanced each other out to result 
in the lack of any observed effect of tight (versus less tight) 
control on the primary perinatal outcome of death or morbidity.
In this secondary, exploratory analysis, we sought to exam-
ine the relationship between gestational age at randomization 
and major CHIPS outcomes (including birth weight <10th 
centile and preterm birth) to investigate whether the maternal 
benefits of tight control could be achieved by delaying ini-
tiation of antihypertensive therapy until later in pregnancy, 
to minimize any potential negative impact of that therapy on 
fetal growth.
Methods
CHIPS was an open, pragmatic, international multicenter trial. 
Women at 14+0 to 33+6 weeks of gestation with nonproteinuric 
chronic or gestational hypertension, elevated BP (office dBP, 90–105 
or 85–105 mm Hg if on antihypertensives), and a live fetus were ran-
domized (stratified by center and hypertension type) to less-tight (100 
mm Hg) or tight control (85 mm Hg) of BP. Importantly, women had 
to have persistently elevated BP, either on 2 consecutive outpatient 
visits or for 4 hours at the same visit; so many women with chronic 
hypertension became eligible only later in pregnancy following the 
midtrimester nadir.
Data of this secondary analysis will be available on request of the 
author.
CHIPS was approved by the Research Ethics Boards both central-
ly at the University of British Columbia as the coordinating center 
(H08-00882) and locally at all study sites. All participants gave writ-
ten informed consent. The study was designed following the princi-
ples of the Declaration of Helsinki and Guidelines for Good Clinical 
Practice.
The composite primary outcome was pregnancy loss or high-level 
neonatal care (greater than normal newborn care) for >48 hours in 
the first 28 days of life or until primary discharge home, whichever 
was later. The composite secondary outcome was serious maternal 
complications before 6 weeks postpartum or until hospital discharge, 
whichever was later. Serious maternal complications included death, 
stroke, eclampsia, blindness, uncontrolled hypertension, the use of 
inotropic agents, pulmonary edema, respiratory failure, myocardial 
ischemia or infarction, hepatic dysfunction, hepatic hematoma or 
rupture, renal failure, and transfusion, modeled on Delphi consen-
sus.8 Additional major CHIPS outcomes were severe hypertension 
and preeclampsia for the mother and birth weight <10th centile and 
preterm birth for the baby (see Table S2 in the online-only Data 
Supplement for definitions).
For this secondary analysis, there were 981 women (of 987 ran-
domized) available for analysis. Mixed-effects logistic regression 
was used to examine the effect, by gestational age at randomization, 
of less-tight (versus tight) control on major outcomes: primary peri-
natal outcome, preterm birth, birth weight <10th centile, serious ma-
ternal complications, persistent severe maternal hypertension, and 
preeclampsia. An interaction term between gestational age at ran-
domization and treatment group was included to examine treatment 
effect as a function of gestational age at randomization. Gestational 
age was considered categorically in quartiles. Adjustment was made 
for baseline factors as in the primary CHIPS analysis (ie, stratifica-
tion factors of hypertension type and center [as a random effect], 
prior severe hypertension in this pregnancy, in-hospital at enroll-
ment, gestational diabetes mellitus at enrollment, and antihyperten-
sive therapy at enrollment) and those that were different between 
less-tight and tight control in any gestational age quartile (ie, eth-
nicity, aspirin at enrollment, perinatal mortality ratio of recruiting 
country, and systolic BP within 1 week before randomization; Table 
S3). In a sensitivity analysis, we also considered gestational age at 
randomization continuously in either linear or quadratic form, and 
the optimal functional form was selected to provide the best fit to 
the data based on the Akaike information criterion. We conducted 
further subgroup analysis by hypertension type (chronic or gesta-
tional hypertension). Mixed-effects logistic regression was used for 
chronic hypertension, and Firth logistic regression without random 
effects was considered for gestational hypertension because of low 
outcome counts within a gestational age category or baseline factor 
level. A P value <0.05 for an interaction term was considered statis-
tically significant. SAS software, version 9.3 (SAS Institute), was 
used for the statistical analysis.
Results
Of the 981 women in the CHIPS analysis, 493 were in less-
tight and 488 in tight control. The results have been previously 
published.5 In brief, there were 736 (74.6%) women with 
chronic and 251 (25.4%) with gestational hypertension. At 
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baseline, the less-tight and tight control groups were similar. 
Baseline BP was ≈140/92 mm Hg, but just <20% had expe-
rienced severe hypertension earlier in the index pregnancy. 
Just over half of women (566; 57.3%) were on antihyperten-
sive therapy, usually (>80%) labetalol or methyldopa in equal 
measure, regardless of the type of antihypertensive (Table S4). 
Few women were either smokers or had gestational diabetes 
mellitus (≈6% each). Importantly, ultrasonographic assess-
ment of gestational age was performed in 907 (91.9%) women 
(455, 91.5% in less tight and 452, 92.2% in tight).
Table 1. Major CHIPS PERINATAL Outcomes in Less-Tight (vs Tight) Control Groups, According to Gestational Age at 
Randomization (n, Percentage of Women)*†
Outcome and (Sub)Groups Less-Tight Control Tight Control OR (95% CI) P Value
Pregnancy loss or high-level neonatal care >48 h 
  All women (n=981) 155/493 (50.8%) 150/488 (49.2%) 1.01 (0.75–1.34) 0.961
  According to GA at randomization     
   <18 wk (n=226) 33/116 (28.4) 31/110 (28.2) 0.99 (0.54–1.82) 0.971
   18–23 wk (n=238) 42/127 (33.1) 30/111 (27.0) 1.31 (0.72–2.37) 0.380
   24–29 wk (n=251) 47/123 (38.2) 47/128 (36.7) 1.01 (0.58–1.75) 0.977
   30+ wk (n=266) 33/127 (26.0) 42/139 (30.2) 0.81 (0.45–1.43) 0.458
  Interaction: GA and treatment    0.724
Birth weight <10th centile
  All women (n=976) 79/490 (16.1%) 96/486 (19.8%) 0.75 (0.54–1.05) 0.098
  According to GA at randomization     
   <18 wk (n=222) 12/114 (10.5) 29/108 (26.9) 0.30 (0.14–0.65) 0.002‡
   18–23 wk (n=237) 15/126 (11.9) 18/111 (16.2) 0.63 (0.30–1.34) 0.229
   24–29 wk (n=251) 25/123 (20.3) 24/128 (18.8) 1.06 (0.56–2.01) 0.852
   30+ wk (n=266) 27/127 (21.3) 25/139 (18.0) 1.20 (0.65–2.23) 0.561
  Interaction: GA and treatment    0.028‡
Delivery at <37 wk
  All women (n=978) 175/492 (35.8%) 153/486 (31.5%) 1.16 (0.87–1.54) 0.315
  According to GA at randomization     
   <18 wk (n=223) 35/115 (30.4) 22/108 (20.4) 1.72 (0.91–3.27) 0.098
   18–23 wk (n=238) 48/127 (37.8) 27/111 (24.3) 1.73 (0.95–3.15) 0.071
   24–29 wk (n=251) 43/123 (35.0) 53/128 (41.4) 0.66 (0.38–1.14) 0.133
   30+ wk (n=266) 49/127 (38.6) 51/139 (36.7) 1.08 (0.64–1.84) 0.765
  Interaction: GA and treatment    0.061
Delivery at <34 wk
  All women (n=978) 77/492 (15.7%) 61/486 (12.6%) 1.23 (0.84–1.81) 0.295
  According to GA at randomization     
   <18 wk (n=223) 16/115 (13.9) 12/108 (11.1) 1.26 (0.55–2.89) 0.582
   18–23 wk (n=238) 26/127 (20.5) 13/111 (11.7) 1.86 (0.87–3.96) 0.109
   24–29 wk (n=251) 24/123 (19.5) 25/128 (19.5) 0.90 (0.46–1.76) 0.755
   30+ wk (n=266) 11/127 (8.7) 11/139 (7.9) 1.14 (0.46–2.85) 0.774
  Interaction: GA and treatment    0.567
CHIPS indicates Control of Hypertension in Pregnancy Study; CI, confidence interval; GA, gestational age; OR, odds ratio; and sBP, systolic blood 
pressure.
*Randomization was stratified for center and hypertension type; there was no stratification for gestational age.
†Adjustment was made for baseline factors as in the primary CHIPS analysis (ie, stratification factors of hypertension type and center [as a random 
effect], prior severe hypertension in this pregnancy, in-hospital at enrollment, gestational diabetes mellitus at enrollment, and antihypertensive therapy 
at enrollment) and those that were different between less-tight and tight control in any gestational age quartiles (ethnicity, aspirin at enrollment, 
perinatal mortality ratio of recruiting country, and sBP within 1 wk before randomization). An interaction term between gestational age at randomization 
and treatment group was included to examine treatment effect as a function of gestational age at randomization.
‡P values for adjusted OR (see methods) <0.05.
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Post-randomization, in the less-tight (versus tight) group, 
BP was higher (138.8±0.5/89.9±0.3 versus 133.1±0.5/85.3±0.3 
mm Hg; P<0.001), and fewer women took antihypertensive 
therapy (362, 73.4% versus 452, 92.6%; P<0.001), usually 1 
drug (209, 57.7% versus 281, 62.2%) and usually labetalol 
(242, 66.9% versus 304, 67.3%), methyldopa (154, 42.5% 
versus 182, 40.3%), or nifedipine (115, 31.8% versus 136, 
30.1%; Appendix in the online-only Data Supplement5).
Perinatal Outcomes
The effect of less-tight (versus tight) control on the primary 
perinatal outcome did not differ between the treatment groups 
randomized at different gestational ages (Pinteraction=0.724; 
adjusted OR, 1.01 [0.75–1.34]; Table 1). There was, however, 
a significant interaction between treatment group and gesta-
tional age for birth weight <10th centile (Pinteraction=0.028) and 
a trend toward more preterm birth; however, no significant 
effect was seen (Pinteraction=0.061). Less-tight (versus tight) 
control was associated with fewer babies with birth weight 
<10th centile at <18 weeks (OR
adjusted, 0.30 [0.14–0.65]) 
with a similar, nonsignificant effect seen at 18 to 23 weeks 
(OR
adjusted, 0.63 [0.30–1.34]) but no obvious effect at 24 to 29 
or 30+ weeks. Less-tight (versus tight) control was associ-
ated with a nonsignificant increase in preterm birth at <18 
weeks (OR
adjusted, 1.72 [0.91–3.27]) and at 18 to 23 weeks 
(OR
adjusted, 1.73 [0.95–3.15]), with no significant effect from 
24 weeks. A similar pattern was seen for delivery at <34 
weeks, but the results did not reach statistical significance 
(Pinteraction=0.567; Table 1 overall; Table S5 for chronic and 
gestational hypertension subgroups).
These effects are demonstrated graphically in Figure 1 in 
which gestational age was treated as a continuous variable; 
the effects were similar in that less tight (versus tight) at <24 
weeks was associated with both a decrease in birth weight 
<10th centile (small for gestational age; Pinteraction=0.005) and 
an increase in preterm birth at <37 weeks (Pinteraction=0.043), 
with no effect on the primary outcome (Pinteraction=0.354).
In CHIPS, 213 women delivered spontaneously (21.7%; 
109 in less tight and 104 in tight), 442 were induced (45.1%; 
224 in less tight and 218 in tight), and 323 had a caesarean 
before labor (32.9%; 159 in less tight and 164 in tight).5 The 
relationship between less-tight (versus tight) control at <24 
weeks and an increase in preterm birth was restricted to an effect 
on iatrogenic (ie, induced or elective delivery; Pinteraction=0.063) 
and not spontaneous preterm birth (Pinteraction=0.329; Figure 
S1). The reasons for iatrogenic preterm birth were not system-
atically reported in CHIPS.
In subgroup analyses, the overall relationship between ini-
tiation of less-tight (versus tight) control at <24 weeks and 
perinatal outcomes was demonstrable only among women 
with chronic, but not gestational, hypertension, whether gesta-
tional age was analyzed by quartile (Table S5) or continuously 
(Figures S2 and S3).
Maternal Outcomes
There was no demonstrable interaction between gestational age 
at initiation of less-tight versus tight control and serious maternal 
complications when gestational age was considered categorically 
(Table 2). However, when gestational age was considered as a 
Figure 1. Odds ratio and 95% confidence intervals for major 
CHIPS (Control of Hypertension in Pregnancy Study) PERINATAL 
outcomes in less-tight (LT; vs tight [T]) control groups, according 
to gestational age at randomization (wk). Small for gestational 
age (SGA) defined as birth weight <10th centile. The P value 
shown is for the interaction between treatment group and 
gestational age at randomization treated as a continuous variable 
on the relevant outcome.
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continuous variable, later initiation (beyond 24 weeks) of less-tight 
(versus tight) control seemed to be associated with an increase in 
serious maternal complications (Figure 2; Pinteraction=0.205); this 
finding appeared to be related to findings within women with 
gestational hypertension (Figure S3; Table 2 overall; Table S5 
chronic and gestational hypertension subgroups).
Women in less-tight (versus tight) control had more severe 
hypertension overall (OR
adjusted, 1.82 [1.36–2.44]) and in par-
ticular, at <18 weeks (OR
adjusted, 2.49 [1.34–4.63]) and 18 to 
23 weeks (OR
adjusted, 2.43 [1.30–4.55]), with a nonsignificant 
interaction demonstrated with gestational age (Pinteraction=0.336; 
Table 2). However, in sensitivity analyses with gestational age 
as a continuous variable (Figure 2), initiation of less-tight 
(versus tight) control before 28 weeks seemed to be associated 
with more severe hypertension (Pinteraction=0.076). A similar 
nonsignificant trend toward early initiation of less-tight (ver-
sus tight) control being associated with more preeclampsia 
was seen whether gestational age was considered categori-
cally (Pinteraction=0.621; Table 2) or continuous (Pinteraction=0.183; 
Figure 2). In subgroup analyses, the relationship described 
between gestational age at initiation of less-tight (versus tight) 
control and severe hypertension or preeclampsia seemed to be 
similar among women with chronic or gestational hyperten-
sion (Table S5; Figure S3).
Discussion
Main Findings
In this secondary, exploratory analysis of the CHIPS trial 
of less-tight (versus tight) control of nonsevere pregnancy 
Table 2. Major CHIPS MATERNAL Outcomes in Less-Tight (vs Tight) Control Groups, According to 
Gestational Age at Randomization (n, Percentage of Women)*†
Outcome and (Sub)Groups Less-Tight Control Tight Control OR (95% CI) P Value
Secondary outcome (serious maternal complications) 
  All women (n=981) 18/493 (3.7%) 10/488 (2.0%) 1.84 (0.83–4.10) 0.136
  According to GA at randomization     
   <18 wk (n=226) 4/116 (3.4) 2/110 (1.8) 1.87 (0.33–10.65) 0.480
   18–23 wk (n=238) 4/127 (3.1) 3/111 (2.7) 1.14 (0.24–5.36) 0.867
   24–29 wk (n=251) 4/123 (3.3) 4/128 (3.1) 1.07 (0.25–4.58) 0.924
   30+ wks (n=266) 6/127 (4.7) 1/139 (0.7) 7.30 (0.85–62.95) 0.070
  Interaction: GA and treatment    0.490
Severe hypertension
  All women (n=981) 200/493 (40.6%) 134/488 (27.5%) 1.82 (1.36–2.44) <0.001‡
  According to GA at randomization     
   <18 wk (n=226) 52/116 (44.8) 26/110 (23.6) 2.49 (1.34–4.63) 0.004‡
   18–23 wk (n=238) 51/127 (40.2) 23/111 (20.7) 2.43 (1.30–4.55) 0.006‡
   24–29 wk (n=251) 51/123 (41.5) 45/128 (35.2) 1.35 (0.77–2.37) 0.297
   30+ wk (n=266) 46/127 (36.2) 40/139 (28.8) 1.48 (0.85–2.60) 0.168
  Interaction: GA and treatment    0.336
Preeclampsia
  All women (n=979) 241/491 (49.1%) 223/488 (45.7%) 1.14 (0.87–1.49) 0.327
  According to GA at randomization     
   <18 wk (n=226) 59/116 (50.9) 50/110 (45.5) 1.18 (0.68–2.05) 0.564
   18–23 wk (n=237) 60/126 (47.6) 41/111 (36.9) 1.50 (0.86–2.62) 0.153
   24–29 wk (n=251) 58/123 (47.2) 57/128 (44.5) 1.12 (0.66–1.91) 0.673
   30+ wk (n=265) 64/126 (50.8) 75/139 (54.0) 0.90 (0.54–1.51) 0.686
  Interaction: GA and treatment    0.621
CHIPS indicates Control of Hypertension in Pregnancy Study; CI, confidence interval; GA, gestational age; OR, odds ratio; and sBP, 
systolic blood pressure.
*Randomization was stratified for center and hypertension type; there was no stratification for gestational age.
†Adjustment was made for baseline factors as in the primary CHIPS analysis (ie, stratification factors of hypertension type and 
center [as a random effect], prior severe hypertension in this pregnancy, in-hospital at enrollment, gestational diabetes mellitus 
at enrollment, and antihypertensive therapy at enrollment) and those that were different between less-tight and tight control in 
any gestational age quartiles (ethnicity, aspirin at enrollment, perinatal mortality ratio of recruiting country, and sBP within 1 wk 
before randomization). An interaction term between gestational age at randomization and treatment group was included to examine 
treatment effect as a function of gestational age at randomization.
‡P values for adjusted OR (see methods) <0.05.
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hypertension, significant differences in outcomes were found 
according to the gestational age at randomization. At no gesta-
tional age at which randomization to treatment occurred were 
overall outcomes better if a strategy of less-tight (versus tight) 
BP control was pursued. This finding held true when consider-
ing women overall or for those with either chronic or gesta-
tional hypertension.
Less-tight (versus tight) control commenced before 24 
weeks was associated with fewer babies born with birth weight 
<10th centile but more babies born at <37 weeks; impor-
tantly, there was no overall effect on the primary outcome 
of pregnancy loss or high-level neonatal care for >48 hours. 
In the subgroups by type of hypertension, the findings were 
apparent only among women with chronic (not gestational) 
hypertension, among which there was no gestational age inter-
action; of note, by definition, women with gestational hyper-
tension could be diagnosed only from 20 weeks.
For the mother, less-tight (versus tight) control was associ-
ated with more severe maternal hypertension at all gestational 
ages (as reported in the main trial publication), but this was par-
ticularly so when women were randomized before 28 weeks; a 
nonsignificant similar trend was seen in preeclampsia, and the 
effects were not obviously different by type of hypertension. 
Also, less-tight (versus tight) control seemed to be associated 
with more serious maternal complications after 28 weeks and 
particularly among women with gestational hypertension.
Current Literature
Both small for gestational age and preterm birth are surro-
gates for adverse perinatal outcome.9–14 As each increases risk 
of perinatal mortality and morbidity, each is used commonly 
as a primary or secondary outcome in randomized trials, and 
in particular, those in pregnancy hypertension.
It has long been debated in the obstetric literature whether 
antihypertensive therapy in pregnancy may impair uteropla-
cental perfusion and through this, fetal growth and well-being. 
Although this concern has not been clearly documented in 
traditional meta-analysis of randomized trials (49 trials, 4723 
women),2 meta-regression analysis of 34 trials has suggested 
that lowering maternal BP (as in tight control in CHIPS) is asso-
ciated with lower birth weight.3,15 Some studies published after 
this meta-regression analysis confirmed this hypothesis,4,16,17 
whereas others challenged it2; none were able to account fully 
for associated maternal comorbidity or target BP. In addition, 
observational literature has suggested that initiation of anti-
hypertensive therapy early in pregnancy may be a particular 
concern with regard to a negative impact on fetal growth.18 No 
demonstrable effects have been seen on preterm birth.
Although our secondary analysis of CHIPS data support 
these concerns and show that minimizing antihypertensive 
therapy through less-tight control before 24 weeks (through 
less-tight [versus tight] control) may have a favorable effect 
on fetal growth, what we have demonstrated for the first time 
is how a contrasting effect on preterm birth results in no 
impact on perinatal mortality and morbidity—the hard clini-
cal outcomes that are the focus of our concern.
Strengths and Limitations
Strengths of this study relate mainly to the quality of the trial 
data set on which the analyses were based, including its large 
size and international nature, which improves generalizability. 
Gestational age at randomization was ascertained accurately 
at randomization and there was a balance between groups, 
including type of pregnancy hypertension (as a risk factor for 
fetal growth restriction) and use (and nature) of antihyperten-
sive therapy for which the analyses were adjusted.
First, our analysis had limited statistical power to examine 
the relationship between gestational age and outcome because 
as with all trials, the sample size was based on achieving a dif-
ference between groups in the primary outcome. Power was 
improved by considering gestational age as a continuous vari-
able, in addition to categorical. Also, power was particularly 
limited in analyses of women with gestational hypertension 
Figure 2. Odds ratio and 95% confidence intervals for major 
CHIPS (Control of Hypertension in Pregnancy Study) MATERNAL 
outcomes in less-tight (LT; vs tight [T]) control groups, according 
to gestational age at randomization (wk). The P value shown is 
for the interaction between treatment group and gestational age 
at randomization treated as a continuous variable on the relevant 
outcome.
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who made up 25.4% of the study population and by defini-
tion were not randomized before 20 weeks. Second, we used 
earlier gestational age at initiation of less-tight (versus tight) 
control as an unbiased (prerandomization) proxy for dura-
tion of therapy—a postrandomization characteristic. Third, 
our results are relevant to less-tight (versus tight) control 
as applied in the CHIPS trial, although the antihypertensive 
agents used most commonly (ie, primarily labetalol and meth-
yldopa, and to a lesser extent, nifedipine) are those used most 
commonly internationally.
Perspectives
In summary, this secondary exploratory analysis of CHIPS 
data has shown that there is no gestational age at which less-
tight (versus tight) control is the preferred clinical option, for 
women with chronic or gestational hypertension. Although 
this secondary analysis of the CHIPS trial data confirmed 
the hypothesis that initiating less-tight (versus tight) con-
trol at <24 weeks is associated with fewer babies with birth 
weight <10th centile, an effect that was counterbalanced by 
an increase in iatrogenic preterm birth such that there was 
no overall effect on perinatal death or morbidity. In addi-
tion, such early initiation of less-tight (versus tight) control 
was associated with a particular increase in the risk of severe 
hypertension. Initiation of less-tight (versus tight) control 
after 28 weeks may increase serious maternal complications, 
particularly among women with gestational hypertension. 
Future work should address clinicians’ views about timing 
of delivery among women with higher BP and in particular, 
severe hypertension.
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What Is New?
•	An association was found between initiation of less-tight (versus tight) 
maternal blood pressure control with antihypertensive therapy before 24 
weeks of pregnancy and both fewer small-for-gestational-age babies 
and more iatrogenic preterm birth, such that there was no overall effect 
on death or morbidity for babies.
•	Also, we found that although less-tight (versus tight) maternal blood 
pressure control was associated with more-severe hypertension 
throughout pregnancy, the excess risk was particularly marked when 
less-tight control was initiated before 24 weeks.
What Is Relevant?
•	There is no gestational age at which commencement of less-tight (versus 
tight) control is the preferred strategy for mother or baby. Any potential 
gains in fetal growth are balanced by earlier delivery such that perinatal 
mortality and morbidity are unchanged. However, less-tight (versus tight) 
control increases maternal risk.
Summary
This secondary analysis of CHIPS (Control of Hypertension in 
Pregnancy Study) data reinforces the message that at no point in 
pregnancy is less-tight blood pressure control the preferred clinical 
strategy over tight control, from maternal or perinatal perspectives.
Novelty and Significance
